These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 1612895)

  • 1. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland.
    Narayan KM; Moffat MA
    Health Bull (Edinb); 1992 Jan; 50(1):47-53. PubMed ID: 1612895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine.
    Just M; Berger R; Just V
    Dev Biol Stand; 1986; 65():85-8. PubMed ID: 3030863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
    Dennehy PH; Saracen CL; Peter G
    Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM; Baker L; Starr SE; Plotkin SA
    Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
    King SM; Saunders EF; Petric M; Gold R
    Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of two combined measles-mumps-rubella vaccines based on AIK and Edmonston- Zagreb strains of measles virus.
    Mirchamsy H; Nilforoushan MA; Shafyi A; Razavi J; Ashtiani MP; Youssofi I; Sassani A; Fateh G; Nassiri S
    Kitasato Arch Exp Med; 1991 Sep; 64(2-3):141-7. PubMed ID: 1811112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation.
    Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B
    Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of IgG-antibodies to mumps and measles virus in non-vaccinated children.
    Glikmann G; Petersen I; Mordhorst CH
    Dan Med Bull; 1988 Apr; 35(2):185-7. PubMed ID: 3359817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine.
    André FE; Peetermans J
    Dev Biol Stand; 1986; 65():101-7. PubMed ID: 3556770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells.
    Just M; Berger R; Glück R; Wegmann A
    Dev Biol Stand; 1986; 65():25-7. PubMed ID: 3549399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of mumps antibodies after measles-mumps-rubella (MMR) vaccines.
    Ozaki K; Kuno-Sakai H; Kimura M
    Tokai J Exp Clin Med; 1987 Dec; 12(5-6):305-11. PubMed ID: 3508655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan.
    Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM
    J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The development and duration of immunity in children vaccinated against measles with the Edmonston-Zagreb vaccine].
    Borcić B; Smerdel S; Abu Eldan J; Kolić J; Ferdebar M; Kordić D; Mohacek N
    Lijec Vjesn; 1989; 111(4-5):131-4. PubMed ID: 2770398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles, mumps, and rubella antibodies in vaccinated Baltimore children.
    King JC; Lichenstein R; Feigelman S; Luna C; Permutt TJ; Patel J
    Am J Dis Child; 1993 May; 147(5):558-60. PubMed ID: 8488803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
    An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measles, mumps and rubella immunisation in children at risk of infection with human immunodeficiency virus.
    Molyneaux PJ; Mok JY; Burns SM; Yap PL
    J Infect; 1993 Nov; 27(3):251-3. PubMed ID: 8308316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vaccine coverage and levels of protection with triple viral vaccine in a children population].
    Sánchez Serrano LP; Corcuera MT; Molina MP; de Miguel C; Lozano J; Oñorbe JA; Barberá G
    Enferm Infecc Microbiol Clin; 1990; 8(6):384-7. PubMed ID: 2081176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.